AU2001264920A1 - Therapeutic uses of il-1 receptor antagonist - Google Patents

Therapeutic uses of il-1 receptor antagonist

Info

Publication number
AU2001264920A1
AU2001264920A1 AU2001264920A AU6492001A AU2001264920A1 AU 2001264920 A1 AU2001264920 A1 AU 2001264920A1 AU 2001264920 A AU2001264920 A AU 2001264920A AU 6492001 A AU6492001 A AU 6492001A AU 2001264920 A1 AU2001264920 A1 AU 2001264920A1
Authority
AU
Australia
Prior art keywords
receptor antagonist
therapeutic uses
therapeutic
antagonist
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264920A
Inventor
John Ford
Alice Ho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hyseq Inc
Original Assignee
Hyseq Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/576,755 external-priority patent/US6497870B1/en
Application filed by Hyseq Inc filed Critical Hyseq Inc
Publication of AU2001264920A1 publication Critical patent/AU2001264920A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2001264920A 2000-05-22 2001-05-22 Therapeutic uses of il-1 receptor antagonist Abandoned AU2001264920A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US09/576,755 US6497870B1 (en) 2000-05-22 2000-05-22 Therapeutic uses of il-1 receptor antagonist
US09/576,755 2000-05-22
US59584300A 2000-06-15 2000-06-15
US09/595,843 2000-06-15
PCT/US2001/016838 WO2001089549A2 (en) 2000-05-22 2001-05-22 Therapeutic uses of il-1 receptor antagonist

Publications (1)

Publication Number Publication Date
AU2001264920A1 true AU2001264920A1 (en) 2001-12-03

Family

ID=27077063

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264920A Abandoned AU2001264920A1 (en) 2000-05-22 2001-05-22 Therapeutic uses of il-1 receptor antagonist

Country Status (3)

Country Link
US (1) US20030166524A1 (en)
AU (1) AU2001264920A1 (en)
WO (1) WO2001089549A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002319402B2 (en) * 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
WO2003010291A2 (en) * 2001-07-25 2003-02-06 Hyseq, Inc. Treatment of immune disorders and b cell disorders
WO2003082922A1 (en) * 2002-03-28 2003-10-09 Markus Fritzsche Antibody against an epitope of the b. burgdorferi flagellar basal rod protein (fbrp)
JP2006512895A (en) * 2002-06-28 2006-04-20 ドマンティス リミテッド Ligand
US9321832B2 (en) * 2002-06-28 2016-04-26 Domantis Limited Ligand
US8921528B2 (en) * 2004-06-01 2014-12-30 Domantis Limited Bispecific fusion antibodies with enhanced serum half-life
JP2008521870A (en) * 2004-12-02 2008-06-26 ドマンティス リミテッド Anti-IL-1R1 single domain antibody and therapeutic use
AU2006321364B2 (en) * 2005-12-01 2011-11-10 Domantis Limited Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1
WO2008149147A2 (en) 2007-06-06 2008-12-11 Domantis Limited Polypeptides, antibody variable domains and antagonists
US8323635B2 (en) 2007-11-14 2012-12-04 General Regeneratives, Ltd. Methods of using interleukin-1 receptor antagonist as a myeloprotective agent
CN101690801B (en) 2009-10-26 2012-08-01 上海交通大学 Application of interleukin-1 receptor antagonist and medicinal composition thereof
CN109164266B (en) * 2017-11-27 2021-09-24 首都医科大学附属北京友谊医院 Application of cell factor in distinguishing lymphomata-related hemophagocytic syndrome and lymphoma

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL138576A0 (en) * 1998-04-03 2001-10-31 Hyseq Inc A novel interleukin-1 receptor antagonist and uses thereof
US6541623B1 (en) * 1998-04-03 2003-04-01 Hyseq, Inc. Interleukin—1 receptor antagonist and uses thereof

Also Published As

Publication number Publication date
US20030166524A1 (en) 2003-09-04
WO2001089549A3 (en) 2003-07-10
WO2001089549A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
AU2001250205A1 (en) Prostaglandin d2 receptor antagonists
AU2001269046A1 (en) Use of therapeutic benzamide derivatives
AU2001273032A1 (en) Cytokine receptor zcytor17
AU2002252460A1 (en) Human cytokine receptor
AU2001264920A1 (en) Therapeutic uses of il-1 receptor antagonist
AU2002365655A1 (en) 5-ht7 receptor antagonists
AU2001272974A1 (en) Human receptors
AU2001284763A1 (en) Preparation of risperidone
AU2001258533A1 (en) Construction of dies
AU2001277980A1 (en) Human cytokine receptor
AU2002336437A1 (en) Therapeutic uses of complement receptor 2
AU2001271838A1 (en) Human neuropeptide y-like g protein-coupled receptor
AU2001281791A1 (en) Regulation of human lgr4-like g protein-coupled receptor
AU2001260147A1 (en) Regulation of human rta-like g protein-coupled receptor
AU2001223882A1 (en) Receptor
AU2001264900A1 (en) Pharmaceutical use of fibulin-1
AU2002324476A1 (en) Human cytokine receptor
AU2002328569A1 (en) Medicinal compositions containing angiotensin II receptor antagonist
AU2001242485A1 (en) Regulation of human serotonin-like g protein-coupled receptor
AU6012901A (en) Regulation of human g protein-coupled receptor
AU2001238682A1 (en) Human g protein-coupled receptors
AU5621501A (en) Regulation of human ephrin-like receptor
AU3734901A (en) Use of amidines
AU2001261023A1 (en) Use of an ampa receptor potentiator for the treatment of obesity
AU2001242474A1 (en) Regulation of human seven transmembrane-like g protein-coupled receptor